Straits Times Index
3,343.35 +11.65 (+0.35%) S&P 500
5,482.87 +4.97 (+0.09%) Dow
39,164.06 +36.26 (+0.09%) Nasdaq
17,858.68 +53.53 (+0.30%) Bitcoin USD
61,460.21 +470.49 (+0.77%) CMC Crypto 200
1,281.85 +15.70 (+1.24%)
RPRX Jan 2025 20.000 call
- Simply Wall St.
Royalty Pharma plc (NASDAQ:RPRX) is largely controlled by institutional shareholders who own 70% of the company
Key Insights Given the large stake in the stock by institutions, Royalty Pharma's stock price might be vulnerable to...
- GlobeNewswire
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024 at 2:00 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buye
- GlobeNewswire
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumorPivotal Phase 3 clinical study of vorasidenib demonstrated unprecedented efficacy and tolerability; vorasidenib granted priority review with PDUFA date of August 20, 2024Royalty Pharma projects greater than $1 billion in peak sales annually for vorasidenib in the U.S.; potential to generate royalties exceeding $150 million annually Royalty Pharma to host investor call today,
